Multiple Myeloma

Chemotherapy plus lenalidomide was shown to be inferior to high-dose melphalan and ASCT in transplant-eligible patients with newly diagnosed multiple myeloma.

Adding elotuzumab to lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma appears to result in better efficacy and safety.

The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.

The risk for end-stage renal disease that required renal replacement therapy due to multiple myeloma appears to have declined significantly between 2001 and 2010.

A novel regimen of carfilzomib, pomalidomide, and dexamethasone was highly active in a group of heavily pretreated patients with relapsed or refractory multiple myeloma.

Seventy percent of insured patients with multiple myeloma had treatment-related financial burden, including some with household incomes greater than $100,000 a year.

The FDA recently granted priority review status to ixazomib (Takeda) for the treatment of relapsed or refractory multiple myeloma.

Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.

Continuous therapy resulted in delays in first and second progression compared with fixed-duration therapy in patients with newly diagnosed multiple myeloma.

The International Myeloma Working Group has published a revised International Staging System for multiple myeloma that incorporates chromosomal abnormalities.

Eighty percent of patients with advanced multiple myeloma had a clinical response to a new T cell–receptor therapy that used T cells to target cells expressing NY-ESO-1.

The FDA approved the proteasome inhibitor carfilzomib for the treatment of multiple myeloma, when used in combination with lenalidomide and dexamethasone.

Treatment with carfilzomib plus lenalidomide and dexamethasone resulted in high rates of minimal residual disease negativity in patients with newly diagnosed or smoldering high-risk multiple myeloma.

Use of a VD regimen alone to treat patients with transplant-ineligible multiple myeloma was not inferior to VTD or VMP regimens, according to the UPFRONT trial.

Zoledronic acid did not have any antitumor effect in asymptomatic multiple myeloma patients in relapse, but did delay symptomatic progression and bone disease.

Treatment with lenalidomide and the HDAC inhibitor vorinostat may be effective as a maintenance therapy in multiple myeloma patients after autologous transplant.

Autologous stem cell transplant led to significantly longer overall survival than non-transplant strategies in a cohort of elderly patients with multiple myeloma.

The addition of elotuzumab to lenalidomide and dexamethasone improved progression-free survival and overall response rate in relapsed multiple myeloma patients.

Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.

Multiple myeloma patients had better overall survival if they had prior knowledge of having monoclonal gammopathy of undetermined significance.

The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.

The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.

A scoring system that measured frailty in elderly patients with multiple myeloma was able to accurately predict mortality and risk of toxicity.

The International Myeloma Working Group recently published a series of consensus statements discussing the use of MRI in the treatment of multiple myeloma.

A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.